Results and realistic expectations

Reviewed by Julian Douwes M.D., Chief Medical Officer, Klinik St. Georg

Honest outcome reporting matters more than optimistic marketing. Here is what clinical experience across more than 12,000 Lyme disease patients has shown—the successes, the partial improvements, and the cases where treatment did not deliver what patients hoped for.

Editorial disclosure: Lyme Treatment Germany is an educational platform created in partnership with Klinik St. Georg (St. George Hospital) in Bad Aibling, Germany. Our medical content is informed by St. George Hospital's clinical experience. We disclose this relationship transparently. Read our full editorial policy.

Key facts at a glance

Clinical experience base: More than 12,000 Lyme disease patients treated at St. George Hospital since the early 1990s, from over 90 countries.

Three-tier outcome pattern: A substantial proportion experience significant improvement. Some experience partial improvement. A minority do not respond as hoped. We do not use the word "cure."

Timeline: Most patients do not feel better immediately. Improvement typically begins 4–12 weeks after treatment and continues gradually over 6–12 months.

Influencing factors: Duration of illness, co-infection complexity, immune function, overall health, and adherence to follow-up protocols all affect outcomes.

Important context: Outcome data is based on institutional clinical records, not randomized controlled trials. We are transparent about this distinction.

What we observe: three tiers of response

Clinical experience

After three decades of treating Lyme disease with hyperthermia-based protocols, a consistent pattern of outcomes has emerged. We categorize responses into three tiers—not because medicine fits neatly into categories, but because it gives you a realistic framework for understanding what hyperthermia can and cannot do.

For a substantial proportion of patients, hyperthermia-based treatment leads to meaningful, sustained reduction in symptom burden. These patients report significant improvement in pain, fatigue, neurological symptoms, cognitive function, and overall quality of life. Many are able to return to activities they had given up years earlier—working, exercising, traveling, engaging fully in family life.

Some patients in this group achieve near-complete resolution of their symptoms. They describe themselves as "having their life back." While we never use the word "cure"—because Lyme disease biology does not allow us to make that claim with certainty—the functional improvement in this group is often dramatic and sustained over years of follow-up.

Patients in this tier tend to share certain characteristics: they sought treatment relatively earlier in their disease course, had fewer co-infections, had reasonably preserved immune function, and adhered closely to follow-up protocols after treatment.

A meaningful number of patients experience noticeable, measurable improvement that does not reach complete symptom resolution. These patients feel distinctly better than before treatment—they have more energy, less pain, improved cognitive function, and better quality of life—but some symptoms persist at a reduced level.

For many in this group, the improvement is still life-changing. Going from "unable to work or leave the house" to "able to function with manageable symptoms" is a transformation, even if it falls short of the full resolution they hoped for. Some patients in this tier benefit from additional treatment cycles months later, and some continue to improve gradually over the 6–12 months following their initial treatment.

Patients with longstanding disease (10+ years), complex co-infection profiles, or significantly compromised immune function are more likely to fall into this category. This does not mean treatment was unsuccessful—it means the disease complexity exceeds what a single treatment cycle can fully resolve.

A minority of patients do not experience the improvement they were hoping for. We acknowledge this openly because honesty is more important to us than marketing. Some patients complete the treatment program and do not notice significant change in their symptoms.

This does not necessarily mean the treatment "failed" in a biological sense. In some cases, the degree of tissue damage from years of chronic infection may have produced symptoms that persist even after the infection is addressed. In others, undiagnosed conditions (beyond Lyme disease and its co-infections) may be contributing to symptom burden. And in some cases, the infection may be more resistant to treatment than expected.

What we can say is this: every patient in this group received the same thorough evaluation, the same carefully executed treatment, and the same genuine effort from the medical team. Medicine does not guarantee outcomes, and individual variability is significant. When treatment does not produce the hoped-for results, we work with patients to understand why and to identify next steps.

12,000+

Lyme disease patients treated at St. George Hospital since the early 1990s. This clinical experience base informs the outcome patterns described here. Outcomes are based on institutional clinical records and patient follow-up data, not randomized controlled trials.

Factors that influence your outcome

Three decades of clinical observation have identified several factors that consistently appear to influence how patients respond to hyperthermia-based treatment. Understanding these may help you set realistic expectations for your own case.

Duration of illness

Patients treated earlier in their disease course tend to respond more favorably. Those who have been ill for 1–5 years typically respond better than those who have been ill for 15–20 years. However, patients with very long disease histories can and do improve significantly—duration is an influence, not a disqualifier.

Co-infection complexity

Patients with Lyme disease alone tend to respond more straightforwardly than those carrying multiple co-infections (Babesia, Bartonella, Ehrlichia, Mycoplasma, and others). The treatment protocol addresses co-infections, but greater complexity generally means a longer and more variable path to improvement.

Immune function

Patients whose immune systems are still relatively functional tend to respond better. Severe immune suppression or dysregulation can limit the body's ability to capitalize on the immune activation that hyperthermia produces. Pre-treatment immune support aims to address this, but it remains an important variable.

Overall health status

Pre-existing conditions, nutritional deficiencies, hormonal imbalances, mold exposure, heavy metal burden, and general physical resilience all affect how the body responds to treatment and how effectively it recovers. The comprehensive diagnostic workup identifies many of these factors.

Adherence to follow-up

The weeks and months after treatment are critical. Patients who follow the post-discharge protocol—continuing medications, supplements, dietary guidelines, and lifestyle modifications—tend to sustain and build on their improvements. Those who discontinue follow-up prematurely are more likely to plateau or regress.

Psychological and emotional state

This is not about "thinking positive." Chronic illness takes a profound psychological toll. Patients who have supportive environments, realistic expectations, and the emotional resources to navigate a demanding treatment process tend to cope better and perceive their outcomes more constructively.

The timeline for improvement

This is one of the most important things to understand, and one of the most commonly misunderstood: you will not feel better immediately after hyperthermia. In fact, the first week after treatment is typically the worst you will feel during the entire program.

Typical recovery and improvement timeline

Days 1–7: Acute recovery. Fatigue, Herxheimer reaction, flu-like symptoms. Most patients feel worse before they feel better.

Weeks 2–4: Stabilization. Acute symptoms resolve. Some patients begin to notice early signs of improvement. Others feel "flat" but no longer acutely unwell.

Weeks 4–12: Primary improvement window. This is when most patients first recognize meaningful changes—less pain, more energy, clearer thinking, improved sleep.

Months 3–12: Continued gradual improvement. Many patients continue to improve slowly over the following months. The full benefit of treatment may not be apparent for 6–12 months.

This timeline requires patience. It also requires faith in a process that may feel uncertain during the early weeks. We share this information upfront because managing expectations honestly is essential to your experience. If you expect to feel dramatically better two weeks after hyperthermia, you will be disappointed. If you understand that meaningful improvement typically unfolds over months, you will be better equipped to assess your progress accurately.

In their own words

Patient experiences

Real patient accounts provide a perspective that clinical descriptions cannot. We share these not as promises of what you will experience, but as examples of the range of outcomes patients have reported. Each person's experience is unique.

"I did not feel better right away. The first week after treatment was one of the hardest of my life. But at about the six-week mark, I realized I was doing things I had not been able to do in years. By three months, the difference was undeniable. It was not instant, and it was not easy—but it was real."

Michael R., United Kingdom — Treated 2025